Navigation Links
Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Date:5/13/2013

rketing solutions that enhance brand revenue, drive efficiency and lower costs.  Prior to June 2009, Mr. Sirota served as an executive of Pfizer Inc., most recently as Vice President of Pfizer's US Marketing, Commercial Strategy and Innovation and Regional Sales, responsible for the neuroscience and pain franchises.  During his over twenty-year career at Pfizer, Mr. Sirota was responsible for 12 therapeutic areas and more than 25 brands,  including anti-infectives.  He received his B.S. degree in Pharmacy from Rutgers College of Pharmacy and his Master of Business Administration degree from The Wharton School, The University of Pennsylvania.

About Optimer Pharmaceuticals

We are a global biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in the United States and Canada, and developing other fidaxomicin products in the United States and worldwide, both by ourselves and with our partners and licensees. DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration on May 27, 2011, for the treatment of Clostridium difficile-associated diarrhea, or CDAD, in adults 18 years of age and older. Fidaxomicin has also received marketing authorization in other jurisdictions, including the European Union, where it is marketed under the trade name DIFICLIR™ by our licensee, Astellas Pharma Europe. CDAD is the most common symptom of Clostridium difficile infection, or CDI. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including, without limitation, statements related to future roles and contributions of Mr. Sirota at Optimer.
'/>"/>

SOURCE Optimer Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIRâ„¢ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Levi & Korsinsky announces that a ... States District Court for the District of ... Galectin Therapeutics Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt ... Class Period the Company violated federal securities laws by ...
(Date:8/28/2014)... LONDON , Aug. 28, 2014  A candidate ... The Gambia and Mali ... safety trials of potential vaccines aimed at preventing the disease that ... West Africa . Human trials of ... Health (NIH) and GlaxoSmithKline, are to be accelerated with funding from ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, Inc., ... in noninvasive medical monitoring, today announced that the Food ... 3231 OEM/eHealth finger pulse oximeter for use in ... oximeter plugs into a telemedicine hub or kiosk through ... rate in pediatric to adult patients. The Model 3231 ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... New study finds patients who opt for surgery have decreased pain, ... with the spine disease called degenerative spondylolisthesis * ... pain over time compared to those who do not have surgery, ... The Journal of Bone and Joint Surgery ...
... GAITHERSBURG, Md., June 1 Overall survival data in ... GenVec,s ongoing Phase III Pancreatic Cancer Clinical Trial with ... Society of Clinical Oncology Annual Meeting in Orlando, FL. ... ) , , The poster ...
Cached Medicine Technology:Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4TNFerade(TM) Phase III Data Presented at ASCO 2TNFerade(TM) Phase III Data Presented at ASCO 3
(Date:8/28/2014)... (PRWEB) August 28, 2014 Save ... Healthbox tech accelerator program in Tampa. Healthbox Florida ... innovative healthcare companies grow and achieve their goals. ... August 16th, at their launch event at the Mahaffey ... professionals. , Co-founder Matt Schneider commented on the Save ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 As September ... the more than 100 million people who suffer from ... from the Committee on Advancing Pain Research, Care, and ... of Health, is defined as any pain lasting more ... longer. And while chronic pain causes range from injury ...
(Date:8/28/2014)... 2014 ISI Telemanagement Solutions, Inc., ... be sponsoring the 2014 Presidio Exchange this September ... Presidio leadership to engage with the community with ... will be rolling out objectives for representatives to ... the event, ISI will be discussing their growing ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 Commercial growers ... changing, new Kind K5 series LED grow lights, which perform ... Besides the wattage savings, Kind LED lighting needs no cooling ... room requires less cooling as well. Factoring in that they ... LED lighting is less than a year. , For many ...
(Date:8/28/2014)... 2014 Following the death of an 18-year-old ... FDA issued a warning on powdered caffeine products. ... substance that is readily available to consumers, despite the fact ... senior Logan Stiner died from an overdose of caffeine powder. ... the FDA to issue a safety advisory for caffeine powders. ...
Breaking Medicine News(10 mins):Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 3Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:FDA Issues Safety Advisory for Caffeine Powders 2
... ... Legal Hold Pro™ service into doeDiscovery™. Further expanding doeLegal,s capabilities across the entire spectrum ... to offer increased value to all eDiscovery clients. , ... (PRWEB) May 14, 2010 -- doeLegal, ...
... at ethical issues arising from new neuroimaging research suggesting ... injury might be able to communicate. Title: Severe ... Andrew Billings, Larry R. Churchill, and Richard Payne, Summary: ... meaningful existence? The authors contend that "modern neuroscience ...
... ... in science , ... New York, NY (Vocus) May 13, 2010 -- Mount Sinai School of Medicine at ... of genetics and human genome research, and renowned humanists whose work has advanced biomedical ...
... ... for its many customers who have been touched by cancer, CIGNA expands access to all ... ... of access, quality and choice for its many customers who have been touched by cancer, ...
... 20 people over age 65, experts note, , THURSDAY, ... common irregular heartbeat known as atrial fibrillation in a ... and other forms of dementia, new research finds. , ... beat chaotically, causing blood to pool and increasing the ...
... blood test could spot those who need more supplementation, ... Seventy percent of pregnant women in the United States ... What,s more, the regimen of prenatal vitamins that many ... to boost levels when needed, researchers from the University ...
Cached Medicine News:Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 2Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 3Health News:The Hastings Center Report table of contents for May/June 2010 2Health News:The Hastings Center Report table of contents for May/June 2010 3Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 2Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 3Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 4Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 5Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 6Health News:CIGNA and Cancer Treatment Centers of America Reach New Agreement 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 3Health News:Many Pregnant Woman Not Getting Enough Vitamin D 2